Clinical Microbiology and Infection

Papers
(The H4-Index of Clinical Microbiology and Infection is 73. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)
ArticleCitations
Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis1057
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review625
Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study602
Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis551
Follow-up of adults with noncritical COVID-19 two months after symptom onset510
Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study488
Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting484
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society 428
Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis306
European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults304
Female gender is associated with long COVID syndrome: a prospective cohort study296
Novel SARS-CoV-2 variants: the pandemics within the pandemic288
SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis268
BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel258
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors238
Impact of COVID-19 on maternal and neonatal outcomes: a systematic review and meta-analysis236
Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019: a cross-sectional study233
Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain219
Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients215
Field evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres204
Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis196
Viable SARS-CoV-2 in various specimens from COVID-19 patients182
Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study173
Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study146
Recommendations for antibacterial therapy in adults with COVID-19 – an evidence based guideline143
Accuracy of a nucleocapsid protein antigen rapid test in the diagnosis of SARS-CoV-2 infection143
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis142
2020 list of human papillomavirus assays suitable for primary cervical cancer screening141
Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review138
Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity138
Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients—a multinational observational study by the European Confederation of Medical Mycology132
Validation of a commercially available SARS-CoV-2 serological immunoassay130
How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST)128
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1127
Outbreak of Candida auris infection in a COVID-19 hospital in Mexico127
Machine learning for microbial identification and antimicrobial susceptibility testing on MALDI-TOF mass spectra: a systematic review124
Post–COVID-19 chronic symptoms: a postinfectious entity?119
Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs118
Anosmia in COVID-19 patients116
ESCMID COVID-19 living guidelines: drug treatment and clinical management110
Clinical characteristics of ambulatory and hospitalized patients with monkeypox virus infection: an observational cohort study108
The interface between COVID-19 and bacterial healthcare-associated infections106
A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients104
Understanding the role of bacterial and fungal infection in COVID-19104
How to interpret and use COVID-19 serology and immunology tests103
Evaluation of a rapid antigen test (Panbio™ COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19 patients103
How do I manage nocardiosis?101
Stigma at the time of the COVID-19 pandemic100
Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan100
The role of asymptomatic and pre-symptomatic infection in SARS-CoV-2 transmission—a living systematic review99
Detection and infectivity potential of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) environmental contamination in isolation units and quarantine facilities99
Persistent COVID-19 symptoms are highly prevalent 6 months after hospitalization: results from a large prospective cohort97
Pulmonary long-term consequences of COVID-19 infections after hospital discharge95
Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study94
Quantitative SARS-CoV-2 anti-spike responses to Pfizer–BioNTech and Oxford–AstraZeneca vaccines by previous infection status93
Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary—the HUN-VE study93
Clinical course and factors associated with outcomes among 1904 patients hospitalized with COVID-19 in Germany: an observational study92
Staphylococcus aureus bacteraemia mortality: a systematic review and meta-analysis92
Clinical course and outcomes of critically ill patients with COVID-19 infection: a systematic review88
Incidence of invasive pulmonary aspergillosis among critically ill COVID-19 patients88
Evolution of viral quasispecies during SARS-CoV-2 infection87
Neurologic manifestations associated with COVID-19: a multicentre registry87
Risk factors associated with COVID-19-associated pulmonary aspergillosis in ICU patients: a French multicentric retrospective cohort86
Characteristics of 1573 healthcare workers who underwent nasopharyngeal swab testing for SARS-CoV-2 in Milan, Lombardy, Italy83
Antibiotic resistance associated with the COVID-19 pandemic: a systematic review and meta-analysis81
Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns80
ESCMID rapid guidelines for assessment and management of long COVID79
Machine learning in the clinical microbiology laboratory: has the time come for routine practice?78
Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)77
Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients76
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-1975
Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy74
Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation73
0.038887023925781